PMID- 36100735
OWN - NLM
STAT- MEDLINE
DCOM- 20230126
LR  - 20230202
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Linking)
VI  - 25
IP  - 2
DP  - 2023 Feb
TI  - Targeted delivery of nuclear targeting probe for bladder cancer using cyclic 
      pentapeptide c(RGDfK) and acridine orange.
PG  - 375-383
LID - 10.1007/s12094-022-02938-0 [doi]
AB  - PURPOSE: Both cyclic pentapeptide c(RGDfK) and acridine orange (AO) exhibit 
      antitumor effects and cell permeability. This study aimed to evaluate the nuclear 
      targeting efficiency and safety of the nuclear targeting probe for bladder cancer 
      (BCa) synthesized by c(RGDfK) and AO. METHODS: The nuclear targeting probe 
      AO-(cRGDfK)(2) was synthesized from AO hydrochloride, azided c(RGDfK), and a 
      near-infrared skeleton synthesized via click chemistry reactions. The effect of 
      the AO-(cRGDfK)(2) probe on cell viability was assessed in BCa 5637 cells. The 
      tumor cell targeting efficacy of the AO-(cRGDfK)(2) probe was evaluated in BCa 
      cells in vitro and in tumor-bearing mice in vivo. Nuclear-specific accumulation 
      of fluorescence probe in BCa tumor cells was evaluated using laser scanning 
      confocal microscopy (LSCM). Hematoxylin and eosin staining was performed to 
      detect histopathological changes in the spleen, heart, liver, and kidney. 
      RESULTS: The AO-(cRGDfK)(2) probe did not cause a significant reduction in cell 
      viability. LSCM analysis showed that AO-(cRGDfK)(2) exhibited nuclear-specific 
      ambulation in BCa cells and was not accumulated in 293T cells. Also, this probe 
      efficiently targeted tumor cells in the serum and urine samples. In vivo imaging 
      system of tumor-bearing mice showed that ~ 80% percent of fluorescence signal was 
      accumulated in the tumor sites. The probe did not change histopathology in the 
      heart, liver, spleen, and kidney in tumor-bearing mice after the 21-day 
      treatment. CONCLUSIONS: The AO-(cRGDfK)(2) probe exhibited nuclear-specific 
      accumulation in BCa cells without cytotoxicity, which provides an innovative 
      alternative to improve anticancer therapy for BCa.
CI  - (c) 2022. The Author(s), under exclusive licence to Federacion de Sociedades 
      Espanolas de Oncologia (FESEO).
FAU - Qin, Jiaxin
AU  - Qin J
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Liang, Qing
AU  - Liang Q
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Wang, Guangyue
AU  - Wang G
AD  - Graduate School of Bengbu Medical College, Anhui, China.
FAU - Hao, Lin
AU  - Hao L
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Liu, Xing
AU  - Liu X
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Wang, Xinlei
AU  - Wang X
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Hu, Zhengxiang
AU  - Hu Z
AD  - Graduate School of Jinzhou Medical College, Liaoning, China.
FAU - Fang, Gaochuan
AU  - Fang G
AD  - School of Life Sciences, Jiangsu Normal University, Jiangsu, China.
FAU - Xue, Liang
AU  - Xue L
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Li, Rui
AU  - Li R
AD  - Central Laboratory, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Lv, Qian
AU  - Lv Q
AD  - Central Laboratory, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
FAU - Wen, Jiling
AU  - Wen J
AD  - Department of Urology, Shanghai East Hospital Ji'an Hospital, Jiangxi, People's 
      Republic of China.
AD  - Department of Urology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, People's Republic of China.
FAU - Yang, Guosheng
AU  - Yang G
AD  - Department of Urology, Shanghai East Hospital Ji'an Hospital, Jiangxi, People's 
      Republic of China.
AD  - Department of Urology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, People's Republic of China.
FAU - Han, Conghui
AU  - Han C
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. hanchdoctor@st.btbu.edu.cn.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. 
      hanchdoctor@st.btbu.edu.cn.
AD  - School of Life Sciences, Jiangsu Normal University, Jiangsu, China. 
      hanchdoctor@st.btbu.edu.cn.
AD  - Department of Urology, Heilongjiang Provincial Hospital, Heilongjiang, China. 
      hanchdoctor@st.btbu.edu.cn.
FAU - Shi, Zhenduo
AU  - Shi Z
AUID- ORCID: 0000-0001-6185-2985
AD  - Department of Urology, Xuzhou Clinical College of Xuzhou Medical University, 
      Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. zhenduoxuzhou@163.com.
AD  - Department of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. 
      zhenduoxuzhou@163.com.
AD  - School of Life Sciences, Jiangsu Normal University, Jiangsu, China. 
      zhenduoxuzhou@163.com.
LA  - eng
GR  - 82004110/the National Natural Science Foundation of China/
GR  - BE2020758/the Jiangsu Province Key Research and Development Program/
GR  - BE2019637/the Jiangsu Province Key Research and Development Program/
GR  - Xuzhou Health Education Research [2017] No.22/the Xuzhou Medical Outstanding 
      Talents/
GR  - CXTDA2017048/the Jiangsu Medical Innovation Team/
GR  - KC19075/the Key Projects of Xuzhou Science and Technology Plan/
GR  - KC21184/the Key Projects of Xuzhou Science and Technology Plan/
GR  - 2018TD004/the Xuzhou clinical medicine expert team project/
GR  - 202120104/the Jiangxi Province Health Commission Science and technology project/
PT  - Journal Article
DEP - 20220913
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - F30N4O6XVV (Acridine Orange)
RN  - 0 (Fluorescent Dyes)
RN  - TDQ283MPCW (Eosine Yellowish-(YS))
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Acridine Orange
MH  - Fluorescent Dyes
MH  - *Urinary Bladder Neoplasms/drug therapy
MH  - Eosine Yellowish-(YS)
MH  - Kidney
MH  - Cell Line, Tumor
OTO - NOTNLM
OT  - Cyclic pentapeptide RGD-containing peptides1
OT  - In vivo imaging system5
OT  - Laser scanning confocal microscopy4
OT  - Photodynamic therapy3
OT  - RGD-binding integrins2
EDAT- 2022/09/14 06:00
MHDA- 2023/01/27 06:00
CRDT- 2022/09/13 23:26
PHST- 2022/07/20 00:00 [received]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/09/14 06:00 [pubmed]
PHST- 2023/01/27 06:00 [medline]
PHST- 2022/09/13 23:26 [entrez]
AID - 10.1007/s12094-022-02938-0 [pii]
AID - 10.1007/s12094-022-02938-0 [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2023 Feb;25(2):375-383. doi: 10.1007/s12094-022-02938-0. Epub 
      2022 Sep 13.